ARTICLE | Clinical News
Irofulven hydroxymethylacylfulvene (MGI 114): Began Phase III testing
October 30, 2000 8:00 AM UTC
Additional interim results from MOGN's ongoing 50-patient Phase II pancreatic cancer trial are expected to be presented in November at the New Drugs in Cancer Therapy meeting in Amsterdam (see BioCent...